Durvalumab (MEDI4736; anti-PD-L1 inhibitor): To shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy

Minyong Kang, Ja Hyeon Ku

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)S454-S457
JournalTranslational Cancer Research
Volume5
DOIs
StatePublished - 2016

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2016R1A2B4011623).

Cite this